✦ LIBER ✦

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896) : A trial of the Eastern Cooperative Oncology Group

✍ Scribed by David J. Vaughn; Judith Manola; Robert Dreicer; William See; Ralph Levitt; George Wilding

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 74 KB
Volume: 95
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.10782

No coin nor oath required. For personal study only.

✦ Synopsis

Background:

Chemotherapy options for the patients with advanced urothelial carcinoma and renal dysfunction are limited. the authors performed a phase ii trial of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction.

Methods:

Forty-two patients were accrued; 37 eligible patients were treated. patients received paclitaxel 225 mg/m(2) over three hours followed by carboplatin targeted area under the concentration-time curve = 6 mg/ml. minute every three weeks for up to six cycles.

Results:

The median number of cycles received was four (range, one to six). the objective response rate was 24.3% (95% confidence interval, 11.9-41.7%). the median progression free survival was 3 months and the median overall survival was 7.1 months. the number of poor prognostic risk factors (eastern cooperative oncology group performance status > 1 or lung, liver, or bone metastases) significantly predicted for survival. the most common > or = 1 grade 3 toxicities included granulocytopenia (60%) and neurotoxicity (35%).

Conclusions:

Paclitaxel/carboplatin is a chemotherapy option for patients with advanced urothelial carcinoma and renal dysfunction. future trials in chemotherapy development for this patient population are warranted.

📜 SIMILAR VOLUMES

Phase II trial of gemcitabine and doceta

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium : A trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Judith Manola; Daniel J. Schneider; John F. Schwerkoske; Christo 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 1 views

## Abstract ## BACKGROUND Gemcitabine and docetaxel are active agents in advanced urothelial carcinoma. A Phase II trial of this combination was performed to determine the activity and toxicity of these agents in a multiinstitutional setting in patients previously treated with one prior chemothera

Phase III trial of methotrexate, vinblas

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium : A trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Judith Manola; Bruce J. Roth; William A. See; Steven Kuross; Mar 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

## Abstract ## BACKGROUND The regimens of carboplatin plus paclitaxel (CP) and methotrexate, vinblastine, doxorubicin, and cisplatin (M‐VAC) were compared in patients with advanced urothelial carcinoma. ## METHODS Patients with metastatic urothelial carcinoma were randomized to receive either CP

Phase II trial of gemcitabine in patient

Phase II trial of gemcitabine in patients with advanced sarcomas (E1797) : A trial of the Eastern Cooperative Oncology Group

✍ Scott Okuno; Louise M. Ryan; John H. Edmonson; Dennis A. Priebat; Ronald H. Blum 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 1 views

## Abstract ## BACKGROUND The current study was conducted to evaluate the antitumor activity and toxicity of gemcitabine in patients with advanced sarcoma. ## METHODS Twenty‐five patients with advanced sarcomas, who previously were untreated for metastatic disease, were treated on an Eastern Coo

Phase II trial of trimetrexate for patie

Phase II trial of trimetrexate for patients with advanced gastric carcinoma : An Eastern Cooperative Oncology Group Study (E1287)

✍ Ramesh K. Ramanathan; Stuart Lipsitz; Robert F. Asbury; Raman Qazi; Bernard R. G 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 2 views

## BACKGROUND. A Phase II study was conducted to evaluate the response, duration of response, and duration of survival of patients with measurable gastric carcinoma treated with trimetrexate (TMTX) who had not had prior chemotherapy. ## METHODS. Thirty-three patients with unresectable or metast

Vinblastine, ifosfamide, and gallium nit

Vinblastine, ifosfamide, and gallium nitrate—an active new regimen in patients with advanced carcinoma of the urothelium : A Phase II trial of the Eastern Cooperative Oncology Group (E5892)

✍ Robert Dreicer; Kathleen J. Propert; Bruce J. Roth; Lawrence H. Einhorn; Patrick 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

vinblastine, ifosfamide, and gallium nitrate (VIG) as first-line chemotherapy in patients with locally advanced or metastatic carcinoma of the

Phase 2 trial of epothilone B analog BMS

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800) : A trial of the eastern cooperative oncology group

✍ Robert Dreicer; Shuli Li; Judith Manola; Naomi B. Haas; Bruce J. Roth; George Wi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

## Abstract ## BACKGROUND. Paclitaxel and docetaxel are active agents in advanced urothelial cancer. BMS‐247550 (ixabepilone) has activity in preclinical models in paclitaxel resistant models. A phase 2 trial of this epothilone was performed to determine the activity and toxicity of this agent in